약학대학 - 약학대학

  • 교수 약동/약력학
  • 신범수

관심분야

약동-약력학 연구
약물동태 모델링/시물레이션 연구 (IVIVC, PK-PD, PBPK)
방출제어 제형 설계연구

학력

  • (Ph.D.) SungKyunKwan University, Korea (2005)
  • (M.S.) SungKyunKwan, Korea (2001)
  • (B.S.) SungKyunKwan, Korea (1999)

약력/경력

  • 2006.04 ~ 2007.02 미국뉴욕주립대학교 박사후 연구원 2007.03 ~ 2017.08 대구가톨릭대학교 약학대학 전임강사, 조교수, 부교수 2019.09 ~ 현재 성균관대학교 약학대학 부교수

학술지 논문

  • (2023)  Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203).  BIOMEDICINE & PHARMACOTHERAPY.  167, 
  • (2023)  Establishment of an LC-MS/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study.  JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES.  1229, 
  • (2023)  Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography-Tandem Mass Spectrometry Analysis in Rats.  SEPARATIONS.  10,  5
  • (2023)  Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.  JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES.  123688,  1
  • (2023)  Development of an LC–MS/MS Assay and Toxicokinetic Characterization of Hexamethylenetetramine in Rats.  TOXICS.  11,  41
  • (2023)  Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis.  JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY.  14,  19
  • (2023)  Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  67,  1
  • (2022)  Toxicokinetics, Percutaneous Absorption and Tissue Distribution of Benzophenone-3, an UV Filtering Agent, in Rats.  TOXICS.  10,  11
  • (2022)  Combined phototherapy with metabolic reprogramming-targeted albumin nanoparticles for treating breast cancer.  BIOMATERIALS SCIENCE.  10,  24
  • (2022)  Dynamic drug release state and PEG length in PEGylated liposomal formulations define the distribution and pharmacological performance of drug.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY.  76, 
  • (2022)  Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand, Lu-177-DOTA-PSMA-GUL, in rats by using LC-MS/MS.  SCIENTIFIC REPORTS.  12,  1
  • (2022)  Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study.  PHARMACEUTICS.  14,  6
  • (2022)  Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis.  MOLECULES.  27,  6
  • (2022)  Comparison of the exposure assessment of di(2-ethylhexyl) phthalate between the PBPK model-based reverse dosimetry and scenario-based analysis: A Korean general population study.  CHEMOSPHERE.  294, 
  • (2022)  Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.  JOURNAL OF CONTROLLED RELEASE.  343, 
  • (2022)  Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.  66,  1
  • (2021)  Pharmacokinetics of panduratin a following oral administration of a Boesenbergia pandurata extract to rats.  JOURNAL OF FOOD AND DRUG ANALYSIS.  29,  4
  • (2021)  Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.  CLINICAL PHARMACOLOGY & THERAPEUTICS.  109,  4
  • (2021)  Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity.  ADVANCED THERAPEUTICS.  4,  2
  • (2021)  Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.  ANTICANCER RESEARCH.  41,  2

단행본

  • (2020)  약학용어집.  신일서적(주).  공동
  • (2019)  약제학 리뷰 (수정 2판).  도서출판 신일북스.  공동
  • (2019)  생물약제학과 약동학 (수정2판).  도서출판 신일북스.  공동

특허/프로그램

  • GASTRORETENTIVE DRUG DELIVERY DEVICE HAVING EXPANDABLE STRUCTURE AND MANUFACTURING METHOD THEREFOR.  17030064.  20220728.  미국
  • 방출 속도 조절 경구용 약물 전달 장치 및 방출 속도 조절 경구용 약물 전달 장치의 제조 방법.  10-2020-0046821.  20220725.  대한민국
  • 확장형 구조를 갖는 위체류 약물전달장치 및 이의 제조 방법.  10-2020-0058895.  20220620.  대한민국
  • 확장형 구조를 갖는 위체류 약물전달장치 및 이의 제조 방법.  10-2020-0058892.  20211223.  대한민국
  • 위체류 제어 방출형 제제.  10-2018-0037362.  20200513.  대한민국

수상/공훈

  • 약물방출 패턴의 예측 및 설계를 위한 신개념의 인구동태학적 IVIVC 모델링 연구(한국연구재단)
  • 골다공증 치료용 신규 복합 액제 개발 (경기과학기술진흥원)
  • 이뇨제를 포함한 항고혈압 복합제(3종약물)의 제형평가 연구
  • 비글견에서 아세클로페낙과 에소메프라졸 병용투여 효과 연구

학술회의논문

  • (2023)  Development of 3D-printed expanding gastroretentive drug delivery system by applying the design of experiment approach.  2023 International Conference of the Korean Society of Pharmaceutical Sciences and Technology.  대한민국
  • (2023)  Nonlinear pharmacokinetics of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide in rats.  2023 International Conference of the Korean Society of Pharmaceutical Sciences and Technology.  대한민국
  • (2023)  Pharmacokinetics of the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Semaglutide in Rats.  2023 PharmSci 360.  미국
  • (2023)  Extended In Vitro-In Vivo Correlation (IVIVC) Model to Predict the Pharmacokinetics of Ticagrelor Sustained-Release Formulations.  2023 PharmSci 360.  미국
  • (2023)  Pharmacokinetics and Interspecies Scaling of Semaglutide, a GLP-1 Receptor Agonist.  2023 PharmSci 360.  미국
  • (2023)  Development of Oral Bi-layer Tablet of Ruxolitinib.  2023 PharmSci 360.  미국
  • (2023)  Development of a Novel Repeat-action Oral Drug Delivery System for Naproxen and Esomeprazole.  2023 PharmSci 360.  미국
  • (2023)  Prediction of in vivo pharmacokinetics for ticagrelor sustained-release formulations via extended IVIVC model.  CRS 2023 Annual Meeting & Exposition.  미국
  • (2023)  Application of extended IVIVC model to develop sustained-release injections for semaglutide, a GLP-1 receptor agonist.  2023 대한약학회 춘계 국제학술대회.  대한민국
  • (2023)  Novel pulsatile release drug delivery systems of naproxen and esomeprazole: in vitro and in vivo evaluations.  2023 대한약학회 춘계 국제학술대회.  대한민국
  • (2022)  Evaluation of regional brain distribution of semaglutide, a GLP-1 analog, in rats by LC-MS/MS.  2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.  대한민국
  • (2022)  Development of an LC-MS/MS method for the determination of liraglutide, a GLP-1 receptor agonist, to characterize the pharmacokinetics and brain distribution in rats.  2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.  대한민국
  • (2022)  Development of oral sustained-release tablet of ruxolitinib.  2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.  대한민국
  • (2022)  In vitro Release and in vivo PK Profiles of Fulvestrant Sustained Release Formulations with Improved Solubility.  2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.  대한민국
  • (2022)  Brain Distribution of the Therapeutic Peptide Liraglutide by a Novel Liquid Chromatography-Tandem Mass Spectrometry.  2022 Fall International Convention of The Pharmaceutical Society of Korea.  대한민국
  • (2022)  Establishment of In Vitro-In Vivo Correlation (IVIVC) for Aceclofenac with the Active Metabolite Diclofenac.  2022 PharmSci 360 (AAPS).  미국
  • (2022)  Novel LC-MS/MS analyses for Glucagon-Like Peptide-1 (GLP-1) Analogs, Liraglutide, Lixisenatide, and Semaglutide, and Pharmacokinetic Evaluation in Rats.  2022 PharmSci 360 (AAPS).  미국
  • (2022)  Pharmacokinetics and Brain Distribution of the Therapeutic Peptide Semaglutide by a Novel Liquid Chromatography-Tandem Mass Spectrometry.  2022 PharmSci 360 (AAPS).  미국
  • (2021)  Establishment of an IVIVC model for the development of sustained-release formulations: the aceclofenac case study.  2021 Fall International Convention of The Pharmaceutical Society of Korea.  대한민국
  • (2021)  Novel model-based approach for the development of sustained-release injections for liraglutide by applying extended DoE-IVIVC model.  2021 Fall International Convention of The Pharmaceutical Society of Korea.  대한민국